MetrioPharm AG
MetrioPharm AG: New study confirms high efficacy of MP1021
MetrioPharm AG / Miscellaneous Announcement, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- MetrioPharm AG: New study confirms high efficacy of MP1021 in wound healing Zurich, 16th of March 2009: A new study impressively confirms the accelerated wound healing-effect of MP1021, the lead molecule of the MetrioPharm AG. As part of the clinical trial, which was carried out in St. Petersburg, Russia, 112 patients received surgery due to the diagnosis of a prostate enlargement (benign prostate hyperplasia). The patients were divided into two randomized groups, in which one group was treated with antibiotics (standard therapy) and the other group additionally with MP1021. The wound healing process was significantly enhanced in the group treated with the combination of MP1021 and standard therapy. These results confirm the high efficacy of MP1021 in the patients healing process resulting in an approximately 40% reduced hospitalization (three days vs. five days) compared to the control group. The ambulant after hospital discharge was also reduced by eight days (to 16 vs. 24 days). Furthermore, the risk of postoperative inflammatory complications was significantly reduced after the treatment with MP1021. 'These results show, that we are on the right track and that there are potentially a number of further diseases where treatment with MP1021 is indicated', said Dr. Wolfgang Brysch, President of the MetrioPharm AG Supervisory Board. Benign prostate hyperplasia occurs in 50% of the over 60 year-olds and in 90% of the over 80 year-old men. In Germany alone there are approximately 50.000 cases which require surgical treatment every year, whereas in the USA approximately 160.000 surgical interventions are necessary. These data emphasize the high medical and economic potential of MP1021 in the treatment of wound healing by reducing hospitalization and post care periods significantly. About MetrioPharm AG: MetrioPharm AG is a biotechnology company which specializes in the development and approval of smallmolecular compounds for indications with high medical need. The company's pipeline consists of compounds in pre-clinical and clinical development for which MetrioPharm already has a clinical proof-ofefficacy in humans. Current lead molecule is the immune modulator MP1021 for the treatment of severe infections and inflammatory diseases. Company contact: MetrioPharm AG Neuendorfstraße 20B 16761 Hennigsdorf www.metriopharm.com T. +49 (0) 3302 20 234 02 F. +49 (0) 3302 20 234 99 info@metriopharm.com Investor Relations contact: GFEI Gesellschaft für Effekteninformation mbH Hamburger Allee 26-28 60486 Frankfurt am Main www.gfei.de T. +49 (0) 69 743 037 00 F. +49 (0) 69 743 037 22 metriopharm@gfei.de 16.03.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found